Zimmer Biomet Holdings, Inc. v. Mary Insall

108 F.4th 512
CourtCourt of Appeals for the Seventh Circuit
DecidedJuly 12, 2024
Docket23-1888
StatusPublished
Cited by4 cases

This text of 108 F.4th 512 (Zimmer Biomet Holdings, Inc. v. Mary Insall) is published on Counsel Stack Legal Research, covering Court of Appeals for the Seventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Zimmer Biomet Holdings, Inc. v. Mary Insall, 108 F.4th 512 (7th Cir. 2024).

Opinion

In the

United States Court of Appeals For the Seventh Circuit ____________________ No. 23-1888 ZIMMER BIOMET HOLDINGS, INC., Plaintiff-Appellant, v.

MARY N. INSALL, as Executrix of the Estate of John N. Insall, Defendant-Appellee. ____________________

Appeal from the United States District Court for the Northern District of Illinois, Eastern Division. No. 1:22-cv-02575 — Lindsay C. Jenkins, Judge. ____________________

ARGUED JANUARY 19, 2024 — DECIDED JULY 12, 2024 ____________________

Before ST. EVE, LEE, and PRYOR, Circuit Judges. LEE, Circuit Judge. Dr. John Insall, an orthopedic surgeon who specialized in knee reconstruction and replacement, de- veloped and obtained a number of valuable foreign and do- mestic patents involving knee replacement devices and ac- coutrements that he licensed to Zimmer Biomet Holdings, Inc. In exchange, Zimmer agreed to pay substantial royalties to In- sall (which, upon his death, Zimmer paid to his Estate). After Insall’s last patent expired in 2018, Zimmer stopped all 2 No. 23-1888

royalty payments, asserting that its obligation under the roy- alty agreement had expired. The parties submitted the dis- pute to arbitration as required by the agreement, and the Es- tate prevailed. Zimmer then asked the district court to vacate the arbitration award, arguing that enforcement of the con- tract would violate public policy. The district court rejected this argument and confirmed the award. We agree and affirm. I. Factual Background As a medical device company, Zimmer manufactures a va- riety of products, including technology used for knee replace- ments. Zimmer joined forces with Insall in 1991 to develop certain knee replacement devices and related appurtenances ultimately sold under the brand name “NexGen.” Under this plan, Insall would develop and secure patents for these de- vices, and Zimmer would pay royalties to Insall for the right to license, market, and sell them. This arrangement was me- morialized in a written agreement in 1991. It required Zimmer to make royalty payments to Insall until “the expiration of the last to expire of the patents licensed hereunder or so long as Product is sold by ZIMMER, whichever is last to occur.” The parties amended the agreement in 1994. Among other things, Insall promised to work exclusively for Zimmer through January 1, 2011. The parties also agreed to expand the scope of the agreement from the particular knee replacement system identified in the 1991 agreement to “the design and development of all components of any future knee system that is developed in whole or in part in the United States and offered as a standard line product for Zimmer.” As for the royalty payments, they were to encompass Insall’s work on “future knee systems” until “the expiration of the last to ex- pire of the Patents licensed hereunder or on January 1, 2011, No. 23-1888 3

whichever is last to occur.” The parties also added an arbitra- tion provision that required all disputes arising out of or re- lated to the agreement to be submitted for binding arbitration. Portions of the agreement were amended again in 1998. Relevant here, the amended agreement provided: The parties acknowledge that … royalties shall be paid at the rate of 1% of Net Sales Price on all sales of the NexGen Knee and all subsequently developed articles, devices or components mar- keted by Zimmer as part of the NexGen Knee family of knee components and not at the rate provided for sales of “future knee systems.” In a previous arbitration between the parties (referred to as the Persona Arbitration, named after the technology at issue in that dispute), Zimmer’s counsel explained that the 1998 amendments changed the method by which royalties were to be calculated. Rather than being based on the sale of products containing the patented technology, the royalties under the 1998 agreement were based on the sale of items that Zimmer marketed under its “NexGen Knee” family of products. The arbitration provision remained unchanged. Insall’s last patent expired on March 10, 2018, and Zim- mer’s chief patent counsel informed the Estate a few months later that the company would no longer pay royalties to the Estate. By way of explanation, Zimmer asserted that under the Supreme Court decisions Brulotte v. Thys Co., 379 U.S. 29 (1964), and Kimble v. Marvel Entertainment, LLC, 576 U.S. 446 (2015), a licensor may not collect royalties based on an expired patent. In its view, the payment of ongoing royalties under 4 No. 23-1888

the amended agreement ran “counter to the policy and pur- pose of patent laws.” Unsurprisingly, the Estate disagreed, and the parties sub- mitted the dispute for arbitration in late 2019. In a detailed decision, the arbitration panel concluded that Brulotte did not render the royalty provision in the 1998 agreement void and unenforceable. As such, the panel found that Zimmer had breached its obligations to pay royalties to the Estate, ordered Zimmer to pay past-due royalties, and affirmed Zimmer’s ob- ligation to pay royalties to the Estate in accordance with the 1998 agreement. Zimmer then initiated this lawsuit and asked the district court to vacate the award. The Estate responded with a mo- tion to dismiss and moved the district court to confirm the ar- bitration award. The district court agreed with the Estate and confirmed the arbitration award. This appeal followed. II. Scope of Review A. Standard of Review We review a district court’s decision on a motion to vacate or confirm an arbitration award under the Federal Arbitration Act (FAA) de novo. Webster v. A.T. Kearney, Inc., 507 F.3d 568, 571 (7th Cir. 2007). Factual findings are reviewed for clear er- ror. Kinsella v. Baker Hughes Oilfield Operations, LLC, 66 F.4th 1099, 1103 (7th Cir. 2023). We begin by emphasizing that the FAA and Supreme Court precedent establish that “arbitration awards are largely immune from … scrutiny in court.” Nano Gas Techs., Inc. v. Roe, 31 F.4th 1028, 1031 (7th Cir. 2022) (cleaned up). The breadth of our review is “extremely limited.” Chrysler Motors Corp. v. Int’l Union, Allied Indus. Workers of Am., AFL-CIO, 959 No. 23-1888 5

F.2d 685, 687 (7th Cir. 1992). We may not reconsider the merits of an award even when a party argues that the arbitrators made a factual error or even a legal one when interpreting a contract. United Paperworkers Int’l Union, AFL-CIO v. Misco, Inc., 484 U.S. 29, 36 (1987). There is, however, a narrow exception to our tightly pro- scribed review. As discussed more below, “[t]he public policy doctrine allows this court to decide de novo whether [the award at issue] violates public policy.” Chrysler Motors, 959 F.2d at 687 (cleaned up). B. The Federal Arbitration Act Arbitration aims to resolve disputes more efficiently and at a lower cost than traditional litigation. See Sarah Rudolph Cole, Curbing the Runaway Arbitrator in Commercial Arbitration: Making Exceeding the Powers Count, 68 Ala. L. Rev. 179, 184 (2016). In exchange for expediency and finality, however, par- ties trade the right to challenge the substance of the decision- maker’s ruling; as a result, judicial review of arbitral awards is extremely limited and highly deferential. See Affymax, Inc. v. Ortho-McNeil-Janssen Pharms., Inc., 660 F.3d 281, 285 (7th Cir. 2011) (citing Major League Baseball Players Ass’n v. Garvey, 532 U.S. 504

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
108 F.4th 512, Counsel Stack Legal Research, https://law.counselstack.com/opinion/zimmer-biomet-holdings-inc-v-mary-insall-ca7-2024.